Das Produkt wurde korrekt in den Warenkorb gelegt.

discount label
H-YLQPRTFLL-OH
3D-Ansicht

Biosynth logo

H-YLQPRTFLL-OH

Ref. 3D-PP46992

5mg
172,00 €
10mg
248,00 €
50mg
582,00 €
100mg
863,00 €
250mg
1.449,00 €
Voraussichtliche Lieferung in Vereinigte Staaten, am Dienstag 7. Januar 2025

Produktinformation

Name:
H-YLQPRTFLL-OH
Synonyme:
  • NH2-Tyr-Leu-Gln-Pro-Arg-Thr-Phe-Leu-Leu-OH
Beschreibung:

Peptide H-YLQPRTFLL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-YLQPRTFLL-OH include the following: Predicting SARS-CoV-2 epitope-specific TCR recognition using pre-trained protein embeddings Y Han, A Lee - bioRxiv, 2021 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2021.11.17.468929.abstract Integrative immunoinformatics paradigm for predicting potential B-cell and T-cell epitopes as viable candidates for subunit vaccine design against COVID-19 VR Sarma, FA Olotu , MES Soliman - biomedical journal, 2021 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S2319417021000457 Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8+ T cell immunity in CLL and MDS patients SPA Hernandez, DS Hersby, KK Munk - Frontiers in , 2023 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2022.1035344/full Three-doses of BNT162b2 COVID-19 mRNA vaccine establishes long-lasting CD8+ T cell immunity in CLL and MDS patients SP Amaya Hernandez, DS Hersby, KK Munk - bioRxiv, 2022 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2022.05.13.491706.abstract Identification of a promiscuous conserved CTL epitope within the SARS-CoV-2 spike protein S Jiang, S Wu, G Zhao, Y He, X Guo - Emerging microbes & , 2022 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/22221751.2022.2043727 Virus induced lymphocytes (VIL) as a novel viral antigen-specific T cell therapy for COVID-19 and potential future pandemics R Sivapalan, J Liu, K Chakraborty, E Arthofer - Scientific Reports, 2021 - nature.comhttps://www.nature.com/articles/s41598-021-94654-y A Novel Cell Therapy for COVID-19 and Potential Future Pandemics: Virus Induced Lymphocytes (VIL) R Sivapalan, J Liu, K Chakraborty, E Arthofer - bioRxiv, 2020 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2020.11.26.400390.abstract Prediction of SARS-CoV2 spike protein epitopes reveals HLA-associated susceptibility R JP, P DL, D ML, AR Sandoval - 2020 - europepmc.orghttps://europepmc.org/article/ppr/ppr156133 Identification of a potential mRNA-based vaccine candidate against the SARS-CoV-2 spike glycoprotein: A reverse vaccinology approach OA Durojaye , DM Sedzro , MO Idris , AA Yekeen - , 2022 - Wiley Online Libraryhttps://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/slct.202103903 SARS-CoV-2 modulates NK cell responses via induction of HLA-E and triggers expansion of adaptive NK cells during acute infection MZ Hasan , M Claus, N Kruger, S Reusing, E Gall - bioRxiv, 2024 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2024.03.04.583260.abstract SARS-CoV-2 infection induces adaptive NK cell responses by spike protein-mediated induction of HLA-E expression MZ Hasan , M Claus, N Kruger, S Reusing - Emerging Microbes & , 2024 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/22221751.2024.2361019 Phenotypic and Functional Characterization of Natural Killer Cell Receptors in Human and Rhesus Macaque MZ Hasan - 2024 - ediss.uni-goettingen.dehttps://ediss.uni-goettingen.de/handle/11858/15105 dynamics-guided immunoinformatics to explain the binder and non-binder classification of Cytotoxic T-cell epitope for SARS-CoV-2 peptide-based vaccine discovery M Yusuf , W Destiarani , W Widayat, Y Yosua, G Gumilar - Plos one, 2023 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0292156 Rapid Screen for Antiviral T-Cell Immunity with Nanowire Electrochemical Biosensors M Nami , P Han , D Hanlon, K Tatsuno, B Wei - Advanced , 2022 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/adma.202109661 Tcr-epitope binding affinity prediction using multi-head self attention model M Cai, S Bang , H Lee - icml-compbio.github.iohttps://icml-compbio.github.io/2021/papers/WCBICML2021_paper_59.pdf Implementation of a dextramer staining approach to investigate antigen-specific CD8+ T cells LV Wipfler - 2022 - pub.fh-campuswien.ac.athttps://pub.fh-campuswien.ac.at/obvfcwhsacc/content/titleinfo/7638399/full.pdf HLA-A* 02 affinity to SARS-CoV-2 and susceptibility to COVID-19 LN Ribeiro, FS Sanches, VM Lelis - European Journal , 2023 - journals.tmkarpinski.comhttp://journals.tmkarpinski.com/index.php/ejbr/article/view/698 Prediction of SARS-CoV2 spike protein epitopes reveals HLA-associated susceptibility JP Romero-Lopez , M Carnalla-Cortes - Res , 2020 - scholar.archive.orghttps://scholar.archive.org/work/ggqtrb3qyfdnzcwdtjfxcbexge/access/wayback/https://assets.researchsquare.com/files/rs-25844/v1.pdf Development of multi-epitope peptide-based vaccines against SARS-CoV-2 HX Lim , J Lim , SD Jazayeri , S Poppema , CL Poh - Biomedical Journal, 2021 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S2319417020301530 Molecular mimicry of SARS-COV-2 antigens as a possible natural anti-cancer preventive immunization C Ragone, A Mauriello, B Cavalluzzo - Frontiers in , 2024 - frontiersin.orghttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1398002/abstract SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8+ T cell responses B Agerer , M Koblischke, V Gudipati - Science , 2021 - science.orghttps://www.science.org/doi/abs/10.1126/sciimmunol.abg6461 Development of a New Off-the-Shelf Plasmacytoid Dendritic Cell-Based Approach for the Expansion and Characterization of SARS-CoV-2-Specific T Cells A Maino, A Amen, J Plumas, L Bouquet - The Journal of , 2024 - journals.aai.orghttps://journals.aai.org/jimmunol/article-pdf/212/5/825/1653432/ji2300704.pdf

Hinweis:
Unsere Produkte sind nur für Laborzwecke. Für jede andere Verwendung, bitte melden sie sich bei uns.
Marke:
Biosynth
Langzeitlagerung:
Hinweise:

Chemische Eigenschaften

MDL:
Schmelzpunkt:
Siedepunkt:
Flammpunkt:
Dichte:
Konzentration:
EINECS:
Merck:
HS-Code:

Gefahrenhinweise

UN-Nummer:
EQ:
Klasse:
H-Sätze:
P-Sätze:
Flugverbot:
Gefahrenhinweis:
Verpackungsgruppe:
LQ:

Technische Anfrage zu: 3D-PP46992 H-YLQPRTFLL-OH

Bitte verwenden Sie stattdessen den Warenkorb, um ein Angebot oder eine Bestellung anzufordern

Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.

* Obligatorische felder
Willkommen bei CymitQuimica!Wir verwenden Cookies, um Ihren Besuch zu verbessern. Wir schließen Werbung nicht ein.

Bitte beachten Sie unsere Cookie-Richtlinie  für weitere Details oder passen Sie Ihre Einstellungen unter “Konfigurieren” an.